Bio-Path to Present Data at 2024 EHA Congress

Bio-Path Holdings, Inc., a biotechnology firm specializing in innovative cancer drug development, has announced that it will present positive interim findings from its Phase 2 clinical trial of prexigebersen (BP1001) at the 2024 European Hematology Association (EHA) Congress in Madrid, Spain. This announcement underscores the potential of prexigebersen as a significant therapeutic option for acute myeloid leukemia (AML).

Scheduled for June 13-16, 2024, the EHA Congress will feature a poster presentation by Dr. Jorge Cortes, Director of the Georgia Cancer Center. Dr. Cortes will highlight the interim results from Bio-Path's Phase 2 study, which investigates the effectiveness of prexigebersen in combination with decitabine and venetoclax. The data have shown that prexigebersen is not only well-tolerated but also demonstrates substantial efficacy, surpassing the outcomes of frontline therapies for both newly diagnosed and refractory/relapsed AML patients.

Peter Nielsen, Bio-Path's Chief Executive Officer, expressed enthusiasm about the findings. He emphasized that the interim results reinforce prexigebersen’s potential as a safe and effective AML treatment. Nielsen anticipates that presenting these results to a global audience of leading hematologists at the EHA Congress will further validate the drug’s promising clinical benefits.

Details of the Poster Presentation:
- Title: Interim Safety and Efficacy of BP1001 in a Phase II Acute Myeloid Leukemia Study
- Date and Time: Friday, June 14, 2024, at 6:00 PM CEST
- Location: IFEMA Madrid Recinto Ferial, Hall 7
- Abstract Number: P536

About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. is a biotechnology company that leverages its proprietary DNAbilize® technology to develop a suite of targeted nucleic acid cancer therapies. DNAbilize® employs RNAi nanoparticle drugs administered via simple intravenous transfusions. Bio-Path's leading product candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in a Phase 2 study for blood cancers. The company is also exploring BP1001-A, a modified version of prexigebersen, in a Phase 1/1b study aimed at treating solid tumors.

In addition to prexigebersen, Bio-Path is developing BP1002, which targets the Bcl-2 protein, for blood cancers and solid tumors, including lymphoma and AML. Furthermore, the company is preparing to file an Investigational New Drug (IND) application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide designed to inhibit STAT3.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!